KR20240096711A - Lemd1을 표적화하는 암 백신 및 이의 용도 - Google Patents

Lemd1을 표적화하는 암 백신 및 이의 용도 Download PDF

Info

Publication number
KR20240096711A
KR20240096711A KR1020247018738A KR20247018738A KR20240096711A KR 20240096711 A KR20240096711 A KR 20240096711A KR 1020247018738 A KR1020247018738 A KR 1020247018738A KR 20247018738 A KR20247018738 A KR 20247018738A KR 20240096711 A KR20240096711 A KR 20240096711A
Authority
KR
South Korea
Prior art keywords
seq
amino acid
nucleic acid
vaccine
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247018738A
Other languages
English (en)
Korean (ko)
Inventor
지안 얀
안나 슬래거
브래들리 가먼
닐 쿠치
Original Assignee
이노비오 파마수티컬즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이노비오 파마수티컬즈, 인크. filed Critical 이노비오 파마수티컬즈, 인크.
Publication of KR20240096711A publication Critical patent/KR20240096711A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020247018738A 2017-12-13 2018-12-13 Lemd1을 표적화하는 암 백신 및 이의 용도 Pending KR20240096711A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762598329P 2017-12-13 2017-12-13
US62/598,329 2017-12-13
US201762598612P 2017-12-14 2017-12-14
US62/598,612 2017-12-14
KR1020207019769A KR102673699B1 (ko) 2017-12-13 2018-12-13 Lemd1을 표적화하는 암 백신 및 이의 용도
PCT/US2018/065534 WO2019118771A1 (en) 2017-12-13 2018-12-13 Cancer vaccines targeting lemd1 and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207019769A Division KR102673699B1 (ko) 2017-12-13 2018-12-13 Lemd1을 표적화하는 암 백신 및 이의 용도

Publications (1)

Publication Number Publication Date
KR20240096711A true KR20240096711A (ko) 2024-06-26

Family

ID=66734873

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020247018738A Pending KR20240096711A (ko) 2017-12-13 2018-12-13 Lemd1을 표적화하는 암 백신 및 이의 용도
KR1020207019769A Active KR102673699B1 (ko) 2017-12-13 2018-12-13 Lemd1을 표적화하는 암 백신 및 이의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207019769A Active KR102673699B1 (ko) 2017-12-13 2018-12-13 Lemd1을 표적화하는 암 백신 및 이의 용도

Country Status (11)

Country Link
US (2) US11338028B2 (https=)
EP (1) EP3724217A4 (https=)
JP (3) JP7314139B2 (https=)
KR (2) KR20240096711A (https=)
CN (1) CN111479822A (https=)
AU (2) AU2018384824B2 (https=)
BR (1) BR112020011620A2 (https=)
CA (1) CA3084137A1 (https=)
MX (2) MX2020006305A (https=)
RU (1) RU2760984C1 (https=)
WO (1) WO2019118771A1 (https=)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1487877B1 (en) 2001-09-18 2010-10-27 Genentech, Inc. Compositions and methods for the diagnosis of tumors
WO2004021010A2 (en) * 2002-08-30 2004-03-11 Oncotherapy Science, Inc. Method of diagnosing colon and gastric cancers
EP1954826A4 (en) 2005-11-27 2010-05-05 Compugen Ltd NEW NUCLEOTIDE AND AMINO ACID SEQUENCES AND TESTS AND METHOD FOR THEIR USE FOR DIAGNOSIS
DK2091965T3 (da) 2006-10-17 2013-08-05 Oncotherapy Science Inc Peptidvacciner mod cancere, der udtrykker MPHOSPH1- eller DEPDC1-polypeptider
KR101174452B1 (ko) * 2009-05-11 2012-08-16 한국생명공학연구원 대장암 및 전이에 대한 바이오마커, 이를 이용한 대장암 진단 및 치료제 스크리닝
PL391627A1 (pl) * 2010-06-25 2012-01-02 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
JP2014525584A (ja) * 2011-08-31 2014-09-29 オンコサイト コーポレーション 癌の治療および診断のための方法および組成物
US20140315743A1 (en) * 2011-10-03 2014-10-23 Karen Chapman Methods and Compositions for the Treatment and Diagnosis of Ovarian Cancer
AU2013243948A1 (en) * 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
CA2888648C (en) * 2012-12-13 2021-06-08 The Trustees Of The University Of Pennsylvania Wt1 vaccine
WO2017203526A1 (en) * 2016-05-23 2017-11-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of diagnosing cancer using cancer testis antigens

Also Published As

Publication number Publication date
US11338028B2 (en) 2022-05-24
EP3724217A1 (en) 2020-10-21
KR20200096959A (ko) 2020-08-14
AU2018384824B2 (en) 2022-08-04
AU2018384824A8 (en) 2020-07-30
CN111479822A (zh) 2020-07-31
AU2022263546A1 (en) 2022-12-08
US20190175712A1 (en) 2019-06-13
JP2025065334A (ja) 2025-04-17
RU2760984C1 (ru) 2021-12-02
EP3724217A4 (en) 2022-01-12
CA3084137A1 (en) 2019-06-20
JP2023111915A (ja) 2023-08-10
US20220265800A1 (en) 2022-08-25
KR102673699B1 (ko) 2024-06-17
MX2024005404A (es) 2024-08-06
JP7633306B2 (ja) 2025-02-19
WO2019118771A1 (en) 2019-06-20
MX2020006305A (es) 2020-09-17
BR112020011620A2 (pt) 2020-12-08
JP2021506264A (ja) 2021-02-22
JP7314139B2 (ja) 2023-07-25
AU2018384824A1 (en) 2020-07-16

Similar Documents

Publication Publication Date Title
KR102742526B1 (ko) 암 백신 및 이를 이용하는 치료 방법
US11338029B2 (en) Cancer vaccines targeting PRAME and uses thereof
US20240358809A1 (en) Cancer vaccines targeting survivin and uses thereof
US20220265800A1 (en) Cancer vaccines targeting lemd1 and uses thereof
HK40034680A (en) Cancer vaccines targeting lemd1 and uses thereof
JP7554320B2 (ja) メソセリンを標的とするがんワクチンおよびその使用
US12161706B2 (en) Cancer vaccines targeting BORIS and uses thereof
BR112020010542A2 (pt) moléculas de ácido nucleico, vetor, composição, proteínas, usos dos anteriores, e vacinas
HK40104361A (zh) 靶向prame的癌症疫苗和其用途
HK1262085A1 (en) Cancer vaccines and methods of treatment using the same
HK40034677A (en) Cancer vaccines targeting mesothelin and uses thereof
HK1262085B (zh) 癌症疫苗和使用其的治疗方法

Legal Events

Date Code Title Description
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701